Cambridge Cancer Genomics (CCG)

Currently, cancer therapy is a “one-size-fits-all” process for the majority of patients, and only the very rich have access to truly personalized, or precision, oncology. Despite all the recent breakthroughs in cancer treatment, the reality is that first line therapy still fails for 2 out of 3 cancer patients and it can take up to 6 months to realize when a drug isn’t working.

CCG is using blood draws to guide smarter cancer therapy & shorten the time required to know whether treatment is working or not. This gives a clinician more time to alter treatment and reduce unnecessary side effects experienced by the patient.

Through simple blood draws, CCG can also identify relapse an average of 7 months earlier than standard practice. Over time, this continuous monitoring of treatment effectiveness will power better predictions of the best therapeutic strategy.

At CCG, our mission is to use advances in machine learning, AI and big data analysis to power a new type of cancer treatment regimen. Ultimately, we will ensure that each patient has the right treatment to beat their cancer.